Trial Profile

Open-Label, Phase 1 Study of CD19 t-haNK In Subjects With Diffuse Large B-Cell Lymphoma Who Have Received 2 Or More Lines of Therapy And Are Ineligible For Transplant

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cd19 t haNK (Primary)
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors ImmunityBio

Most Recent Events

14 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment with reason the study was stopped was trial not initiated.
08 Aug 2019 Status changed from planning to not yet recruiting.
03 Jun 2019 According to a NantKwest media release, an investigational new drug application (IND) for Cd19-t-haNK has cleared FDA review.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com